CSL Annual Report 2022

CSL Limited Annual Report 2021/22 52 9 Social Supporting patients with haemophilia In May 2022, CSL Behring announced a groundbreaking new partnership with the World Federation of Hemophilia (WFH). Commencing in 2023, CSL Behring will donate 500 million international units (IUs) of coagulation factor therapy to the WFH as part of its continued support of the WFH Humanitarian Aid Program. The donation, which includes product specifically manufactured for the purposes of being donated, will create consistent and reliable access to treatment for people living with bleeding disorders in more than 60 developing countries. By manufacturing product specifically for the purposes of donation, the coagulation factor therapy will have a standard shelf life of three years, thus enabling greater access to these life-saving therapies for people around the world. The donated product will be delivered twice a year for five years. In addition to the product donation, the partnership supports progress in improving the diagnosis and treatment of bleeding disorders through the WFH’s Global Alliance for Progress (GAP). CSL Behring will provide financial support for logistics costs and training programs designed to address unmet needs for people living with haemophilia in developing countries who are undiagnosed, untreated, or undertreated. This substantive partnership extends CSL Behring’s longstanding commitment to the WFH, with CSL Behring currently in its fifth multiyear commitment to donate coagulation factor therapies to the WFH. The role of real world evidence (RWE) in driving vaccine value and access Unlike other viruses, such as human papillomavirus (HPV) or measles, the influenza virus can change significantly each year, making it critical for us to assess seasonal vaccine effectiveness through real world evidence, year after year. As a company on the front line of influenza prevention, CSL Seqirus is committed to using RWE to continually evaluate the clinical benefit and cost effectiveness of our innovative seasonal influenza vaccines compared to more traditional options. Health agencies use RWE to make decisions about which influenza vaccines to recommend for certain populations, providing access for the most vulnerable people through governmentfunded immunisation programs. In June 2021, CSL Seqirus published a study showing cost-effectiveness of FLUCELVAX QUADRIVALENT in people aged 50 years and above in the UK, lending support to the UK Governments decision to include this cohort in its national influenza vaccination program during the COVID-19 pandemic. In June 2022, the US Advisory Committee on Immunisation Practices of the CDC evaluated the body of evidence including clinical and observational data to preferentially recommend three adjuvanted or higher dose influenza vaccines, including FLUAD, for people 65 years of age and older in the US. This decision will also help improve access to these vaccines for ethnic and racial minorities in this vulnerable age group Social investment CSL’s approach to community support is guided by our Code of Responsible Business Practice and supplemented by our Global Community Contributions Policy. The policy applies to all CSL businesses and employees and is intended to be implemented to guide decision-making and management of any form of community contribution, financial or by other means. The core of the policy is our community contributions framework, which sets out our key focus areas of support: patient communities, innovation and science and local communities. In 2021/22, CSL contributed US$50 million to support global efforts where we operate. 50%^ 49%^ to patient communities to innovation and science 2%^ to local communities US$50 million in community contributions Sub focus areas • Enhancing quality of life for patients in the conditions our therapies treat. • Improving access to our biological medicines. • Advancing knowledge in medical and scientific communities. • Fostering the next generation of medical researchers. • Supporting community efforts where we live and work. • Supporting communities in times of emergency. ^Due to rounding, percentages do not total 100.